Given its upregulation in NCB tumors across inhouse and public dataset (Fig. 7b), we hypothesized that MAP2 might promote cytoskeletal remodeling, enabling tumor cell plasticity and evasion of VEGF and PARP inhibition. The gene discussed is VEGFA; the disease is neoplasm.